Cialis and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

What Is the Actual Interaction Between Tadalafil and Progesterone HRT?

The interaction between tadalafil and oral progesterone HRT is best classified as pharmacodynamic rather than a classic pharmacokinetic drug-drug interaction (DDI). Tadalafil inhibits phosphodiesterase type 5 (PDE5), which prolongs smooth-muscle relaxation and produces vasodilation. Oral micronized progesterone (Prometrium 100 to 300 mg) produces sedation through positive allosteric modulation of GABA-A receptors via its neuroactive metabolite allopregnanolone. When both agents are taken in the same evening window, patients may experience additive dizziness, orthostatic hypotension, and sedation.

The Pharmacodynamic Overlap

Tadalafil's vasodilatory action lowers systolic blood pressure by a mean of 8 to 9 mmHg in healthy volunteers, as documented in the FDA-approved prescribing information for Adcirca/Cialis. Oral progesterone can also reduce systemic vascular resistance, partly through its effect on the vascular endothelium and partly through CNS-mediated relaxation. The combination does not produce the catastrophic hypotension seen with nitrates plus PDE5 inhibitors, but the additive pressure reduction is clinically meaningful in patients who are older, who have orthostatic tendencies, or who take antihypertensives.

The CYP3A4 Pharmacokinetic Component

Tadalafil is exclusively metabolized by CYP3A4 to an inactive catechol glucuronide. Strong CYP3A4 inhibitors such as ketoconazole (400 mg daily) raise tadalafil AUC by 312%, and ritonavir (200 mg twice daily) raises it by 124%, according to the tadalafil FDA label. Progesterone itself is a CYP3A4 substrate and exhibits weak inhibitory activity at the CYP3A4 active site, but it is not classified as a moderate or strong inhibitor in the FDA Drug Interaction Guidance. At clinical HRT doses (100 to 200 mg nightly), the impact on tadalafil plasma concentrations is expected to be minimal.

What the Research Does and Does Not Show

No dedicated clinical trial has examined the tadalafil, progesterone combination head to head. Mechanistic inference relies on the known CYP3A4 profiles of both drugs and on the allopregnanolone pharmacology literature. A 2019 review in the Journal of Clinical Endocrinology and Metabolism characterized oral micronized progesterone's neurosteroid metabolism and confirmed that allopregnanolone levels are meaningfully elevated for 4 to 6 hours after a 200 mg oral dose. Tadalafil's vasodilatory trough occurs at its Cmax near 2 hours post-dose. The temporal overlap of these windows justifies the clinical caution, even without a dedicated DDI trial.

How Tadalafil Works: PDE5 Inhibition and Vascular Effects

Tadalafil selectively inhibits PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. By sustaining cGMP, tadalafil prolongs nitric-oxide-mediated relaxation of smooth muscle in penile erectile tissue, pulmonary vasculature, and the bladder neck. The drug is FDA-approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH) under the brand name Adcirca.

Dosing Regimens Affect the Interaction Window

Two tadalafil dosing strategies exist and each creates a different interaction window:

• As-needed dosing: 10 mg or 20 mg taken 30 to 60 minutes before sexual activity. The Cmax arrives within 2 hours; the drug remains detectable for up to 36 hours given its ~17.5-hour half-life.
• Daily dosing: 2.5 mg or 5 mg once daily, used for BPH or ED. Steady-state plasma concentrations build over 5 days.

Patients on daily tadalafil have a continuously present drug effect, so the CYP3A4 and pharmacodynamic considerations with progesterone apply around the clock rather than in a narrow post-dose window. This matters for patients on nightly oral progesterone who also take daily tadalafil 5 mg for BPH, a combination that is increasingly common as men with low testosterone receive concurrent PDE5 inhibitor therapy.

Tadalafil Blood-Pressure Effects: The Evidence Base

A crossover trial by Kloner et al. Published in the American Journal of Cardiology examined tadalafil 10 mg in men with stable coronary artery disease and found no clinically significant additional blood pressure reduction beyond placebo. The same study confirmed that tadalafil does not potentiate the hypotensive effects of alcohol to a dangerous degree at single doses. Nonetheless, pooled data from phase 3 registration trials show mean systolic decreases of 1 to 5 mmHg during chronic daily dosing, an effect that can be additive with other vasodilators.

How Oral Progesterone HRT Works: Neurosteroid Pathway and Sedation

Oral micronized progesterone (Prometrium, 100 to 200 mg) is prescribed as the progestogen component of menopausal HRT, either cyclically (10 to 14 days per cycle) or continuously alongside estrogen. Unlike synthetic progestins such as medroxyprogesterone acetate, micronized progesterone undergoes first-pass hepatic metabolism to neuroactive steroids, particularly allopregnanolone and pregnanolone.

The Allopregnanolone Sedation Mechanism

Allopregnanolone is a potent positive allosteric modulator of the GABA-A receptor, producing effects broadly similar to benzodiazepines in their mechanism, though not their structure. A pharmacokinetic study by Nahoul et al., cited in the endocrine literature on NCBI Bookshelf, demonstrated that a single 200 mg oral progesterone dose raises allopregnanolone plasma levels to approximately 2 to 4 nmol/L within 1 to 2 hours, a concentration sufficient to produce measurable sedation on validated scales.

This is why the Prometrium FDA prescribing label specifically advises administration at bedtime and warns that "dizziness, abdominal cramps, headache, breast pain/tenderness, musculoskeletal pain, mood swings/depression, and hot flashes" are the most common adverse events, with sedation notable enough to warrant a bedtime dosing recommendation.

Progesterone and Blood Pressure: A Secondary Signal

Beyond sedation, progesterone has a weak aldosterone-antagonist effect through competitive binding at the mineralocorticoid receptor. This can produce modest natriuresis and mild blood-pressure lowering in some patients, as reviewed in a 2015 analysis in Hypertension. The magnitude is small (1 to 3 mmHg systolic in most patients), but it is directionally additive with tadalafil's vasodilation.

Clinical Severity of the Interaction: How Serious Is It?

Most clinical DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the tadalafil, progesterone interaction as minor to moderate, not contraindicated. The absence of a contraindication reflects the lack of documented serious adverse events in published case reports or spontaneous pharmacovigilance data. The FDA Adverse Event Reporting System (FAERS) does not list a notable signal for this pair as of the most recent public data extracts.

Populations at Higher Risk

Certain patients deserve additional scrutiny:

• Older adults (age over 65): Both drugs contribute to fall risk. The American Geriatrics Society Beers Criteria flags PDE5 inhibitors as potentially inappropriate in older men with syncope history.
• Patients on concurrent antihypertensives: Adding two additional blood-pressure-lowering agents (tadalafil plus progesterone) to an existing antihypertensive regimen may produce meaningful orthostatic hypotension, particularly with alpha-blockers. The tadalafil label carries an explicit warning about combining tadalafil with alpha-blockers such as tamsulosin.
• Transgender women on feminizing HRT: Some transgender women use both high-dose oral progesterone (as part of a regimen including estradiol) and tadalafil for sexual function. Doses in this context may exceed standard post-menopausal HRT doses (up to 300 mg nightly is sometimes prescribed off-label), amplifying the sedation and vasodilatory signals.
• Patients with hepatic impairment (Child-Pugh B or C): Both tadalafil and progesterone are hepatically metabolized. Reduced CYP3A4 capacity may raise tadalafil AUC even without a strong drug inhibitor present, meaning progesterone's weak CYP3A4 modulation could tip the balance more noticeably.

Comparing to the Truly Dangerous DDIs with Tadalafil

For perspective: nitrates (nitroglycerin, isosorbide dinitrate) combined with tadalafil are absolutely contraindicated because they produce a synergistic cGMP surge that can drop blood pressure by 50 mmHg or more, causing syncope or myocardial infarction. Strong CYP3A4 inhibitors such as ritonavir, ketoconazole, and clarithromycin carry dose-cap recommendations (tadalafil maximum 10 mg per 72 hours when co-administered with ritonavir). The progesterone interaction occupies a far lower risk tier than either of these.

Drug Interaction Mechanism Summary

The table below consolidates the mechanistic pathways and their clinical weight for quick clinical review.

| Mechanism | Tadalafil Effect | Progesterone Effect | Net Clinical Risk | |---|---|---|---| | CYP3A4 metabolism | Substrate (sole pathway) | Substrate; weak inhibitor | Minor AUC increase in tadalafil possible; not clinically validated at HRT doses | | Vasodilation / BP lowering | 1 to 9 mmHg systolic decrease | 1 to 3 mmHg via mineralocorticoid antagonism | Additive; clinically relevant mainly in older adults or with concurrent antihypertensives | | CNS / sedation | Mild dizziness at therapeutic doses | Moderate sedation via allopregnanolone and GABA-A modulation | Additive dizziness and fall risk, especially in the first 2 to 4 hours after oral progesterone | | P-glycoprotein (P-gp) | Tadalafil is not a notable P-gp substrate | Progesterone has minimal P-gp interaction | Negligible | | Nitric oxide pathway | PDE5 inhibition sustains cGMP | No direct effect on nitric oxide | Not additive in the cGMP pathway |

Monitoring and Dose-Adjustment Guidance

Blood Pressure and Orthostatic Vital Signs

Patients starting tadalafil while already on progesterone HRT (or vice versa) should have supine and standing blood pressure measured at baseline and again at 4 to 6 weeks. A standing systolic drop of 20 mmHg or greater, or a standing diastolic drop of 10 mmHg or greater, meets the clinical threshold for orthostatic hypotension per the ACC/AHA 2017 Hypertension Guidelines. If orthostasis is confirmed, adjusting the timing of doses (not necessarily reducing them) is the first-line intervention.

Timing Optimization

The simplest mitigation strategy is temporal separation. Oral progesterone taken at bedtime (10:00 PM) reaches peak allopregnanolone levels at roughly midnight and returns toward baseline by 4:00 to 6:00 AM. Tadalafil as-needed, if timed for morning or early afternoon activity, sits outside this sedation window entirely. For patients on daily tadalafil 5 mg, timing separation is less practical, so monitoring and fall-prevention counseling take priority.

Dose Adjustment

No regulatory body currently recommends a progesterone dose reduction specifically because of tadalafil co-administration. The tadalafil label recommends dose reduction only for strong CYP3A4 inhibitors (as noted: maximum 10 mg per 72 hours with ritonavir) and for renal impairment (CrCl <30 mL/min). Progesterone at standard HRT doses (100 to 200 mg) does not qualify for either category. A clinician may choose empirically to use the lower 100 mg progesterone dose in an elderly patient already on daily tadalafil, but this is a clinical judgment rather than a guideline-mandated adjustment.

Patient Counseling Points

What to Tell Patients Taking Both Medications

Clear, actionable language matters more than a complete pharmacology lecture. Patients should understand:

1. Take oral progesterone at bedtime as the label directs, and be aware that the first 4 to 6 hours after the dose is the window of maximal sedation and potential dizziness.
2. Avoid standing up quickly during that window, especially to use the bathroom at night. Hold the bed rail or wall for a moment before walking.
3. Do not combine tadalafil with alcohol on the same evening as oral progesterone. Alcohol is itself a CNS depressant and a mild vasodilator; the three-way combination amplifies fall risk.
4. Report persistent dizziness or light-headedness to your prescriber. These symptoms are not expected to be severe, but they should not be dismissed.
5. Never add a nitrate (including recreational nitrites/poppers) to this combination. That remains an absolute contraindication regardless of the progesterone.

A Note for Prescribers

"The concomitant use of tadalafil in patients taking alpha-1 blockers may lead to symptomatic hypotension in some patients," states the Cialis prescribing information, Section 7.1. While that warning targets alpha-blockers, not progesterone, it illustrates the FDA's reasoning: any agent that lowers blood pressure independently can produce additive effects with tadalafil. Progesterone belongs to that broader category and deserves the same thoughtful co-prescribing approach.

Special Considerations: Pulmonary Arterial Hypertension

Tadalafil 40 mg once daily (brand Adcirca) is FDA-approved for PAH. Women with PAH are frequently of childbearing age or in the peri-menopausal transition, and some receive progesterone as part of a contraceptive or HRT regimen. The PHIRST trial (N=405) showed that tadalafil 40 mg improved 6-minute walk distance by 33 meters versus placebo at 16 weeks in PAH patients (Galie et al., JACC 2009). In this population, the baseline hemodynamic compromise means that even a 2 to 3 mmHg additional blood pressure drop from progesterone warrants formal monitoring rather than reassurance alone. PAH clinicians should document the progesterone dose, route, and timing in the medication reconciliation record.

Tadalafil Interactions That Actually Require Dose Adjustment (for Context)

Understanding where the progesterone interaction sits requires knowing what the genuinely serious tadalafil DDIs look like:

• Nitrates (all forms): Absolute contraindication. The FDA label states this without qualification.
• Ritonavir and other strong CYP3A4 inhibitors: Tadalafil maximum dose 10 mg per 72 hours per the label.
• Alpha-blockers (tamsulosin, doxazosin): Use with caution; initiate tadalafil at lowest dose. Combination with doxazosin 8 mg produced symptomatic hypotension in 4 of 45 subjects in a phase 1 trial.
• Antifungals (ketoconazole 400 mg): AUC increased 312%; limit tadalafil dose.
• Moderate CYP3A4 inhibitors (fluconazole, erythromycin): Use with caution; no mandated dose cap but monitor.
• Progesterone HRT at standard doses: Minor pharmacokinetic effect, additive pharmacodynamic effects. No mandated dose adjustment. Monitor clinically.

This hierarchy matters when communicating risk to patients who may conflate "drug interaction" with "you cannot take these together."

Evidence Gaps and What Future Research Should Address

The current literature has a clear gap: no randomized crossover pharmacokinetic study has directly measured tadalafil AUC and Cmax in the presence of steady-state oral micronized progesterone at doses of 100 mg and 200 mg. Such a study in 20 to 30 healthy volunteers across the relevant populations (post-menopausal women, transgender women) would settle the CYP3A4 question definitively. A secondary endpoint measuring allopregnanolone levels alongside blood pressure readings at 1, 2, 4, and 8 hours post-dosing would characterize the pharmacodynamic overlap window with precision.

The absence of this data does not mean the interaction is harmless. It means the risk characterization relies on mechanism-based prediction rather than direct measurement, which is a weaker form of evidence.